Recent developments to share with you

Quality is the lifeline of an enterprise – its core and soul.

2025-01-26


Quality is the lifeline of an enterprise – its core and soul. To further standardize our R&D processes, effectively manage risks, and establish standardized operations and management practices, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. passed the ISO 9001 Quality Management System (CNAS) certification in January 2025.

Achieving ISO 9001 (CNAS) certification demonstrates our company's capabilities and serves as an incentive for future growth. We will continue to optimize and standardize our management systems, improve the effectiveness of our quality management system, enhance our management level, and drive the rapid development of the company.

 

Keywords:

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03